Fax: (310) 794-2538
Variation in the delivery of care
Version of Record online: 11 JUL 2011
Copyright © 2011 American Cancer Society
Volume 117, Issue 23, pages 5392–5401, 1 December 2011
How to Cite
Chamie, K., Saigal, C. S., Lai, J., Hanley, J. M., Setodji, C. M., Konety, B. R., Litwin, M. S. and The Urologic Diseases in America Project (2011), Compliance with guidelines for patients with bladder cancer. Cancer, 117: 5392–5401. doi: 10.1002/cncr.26198
We acknowledge the efforts of the Applied Research Program at the National Cancer Institute; the Office of Research, Development, and Information at the Centers for Medicare and Medicaid Services; Information Management Services Inc; and the Surveillance, Epidemiology, and End Results (SEER) program tumor registries in the creation of the SEER-Medicare database.
This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. Dr. Chamie had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
- Issue online: 18 NOV 2011
- Version of Record online: 11 JUL 2011
- Manuscript Accepted: 24 MAR 2011
- Manuscript Revised: 22 MAR 2011
- Manuscript Received: 16 FEB 2011
- 5Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer. 2009; 115: 2660-2670., , , et al.
- 8Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40( 8 suppl): IV-3-IV-18., , , , .
- 9Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002; 40( 8 suppl): IV-19-IV-25., , , , .
- 16BCG immunotherapy in bladder cancer. In: Rouse SN, ed. Urology Annual. Los Angeles: Appleton and Lange; 1987: 67..
- 21Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol. 1997; 79: 731-735., , , , .
- 24A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol. 1993; 149: 749-752., , , , , .
- 25Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study–FinnBladder III long-term results. J Urol. 2002; 168: 981-985., , , , .
- 26Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study–Finnbladder III. J Urol. 1999; 161: 1133-1135; discussion 1135-1136., , , et al.
- 27The robot is in— and ready to operate. Business Week: March 14, 2005: 110-112..
- 32Surveillance, Epidemiology and End Results (SEER) Program. http://www.seer.cancer.gov. Accessed October 2010.
- 33Federal Interagency Forum on Aging-Related Statistics. Older Americans Update 2006: Key Indicators of Well-Being. Washington, DC: US Government Printing Office; 2006.